when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
calendar
approval

approval

EVRYSDI (RISDIPLAM) — FDA approval

September 17, 2024EVRYSDIupdated 5mo ago

community read0 votes

Sponsor: GENENTECH INC. Form: FOR SOLUTION. Route: ORAL

view source ↗

Data sources

last refreshed 5mo ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

drug timeline · 8

approvalEVRYSDI (RISDIPLAM) — FDA approvalFeb 10, 2026 · 241d ago
approvalEVRYSDI (RISDIPLAM) — FDA approvalFeb 10, 2026 · 241d ago
approvalEVRYSDI (RISDIPLAM) — FDA approvalJan 21, 2026 · 261d ago
approvalEVRYSDI (RISDIPLAM) — FDA approvalJan 21, 2026 · 261d ago
approvalEVRYSDI (RISDIPLAM) — FDA approvalJan 21, 2026 · 261d ago
approvalEVRYSDI (RISDIPLAM) — FDA approvalFeb 11, 2025 · 605d ago
approvalEVRYSDI (RISDIPLAM) — FDA approvalFeb 11, 2025 · 605d ago
approvalEVRYSDI (RISDIPLAM) — FDA approvalFeb 29, 2024 · 953d ago

same company · ±60 days · 6

approvaltocilizumab: ACTEMRA (TOCILIZUMAB) — FDA approvalSep 19, 2024
approvaltocilizumab: ACTEMRA (TOCILIZUMAB) — FDA approvalSep 19, 2024
approvaltocilizumab: ACTEMRA (TOCILIZUMAB) — FDA approvalSep 20, 2024
approvaltocilizumab: ACTEMRA (TOCILIZUMAB) — FDA approvalSep 20, 2024
approval(atezolizumab + hyaluronidase (human recombinant)): TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approvalSep 12, 2024
approvalinavolisib: ITOVEBI (INAVOLISIB) — FDA approvalOct 10, 2024

🐶 often sniffed alongside

top 4

drugrisdiplam64 co-mentions · 16 sources
tagApproval64 co-mentions · 16 sources
companyGenentech Inc32 co-mentions · 16 sources
tagSmall Molecule32 co-mentions · 16 sources

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?